Guardian Pharmacy Services Inc. Class A Common Stock (GRDN)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style skeptic and a Buffett-style business appraiser. Guardian Pharmacy Services serves lower-acuity long-term care facilities - assisted living, behavioral health, group homes - through technology-enabled pharmacy and clinical services. The filed record is short. In FY2024, the year ended 2024-12-31, revenue was $1.2B and net income was a loss of $110.0M. In FY2025, the year ended 2025-12-31, revenue was $1.4B and net income was $49.2M. That swing is meaningful. The latest filed quarter, fiscal Q2 2026, ended 2026-06-30, showed revenue of $351.8M and net income of $21.9M; fiscal Q2 2025, ended 2025-06-30, showed revenue of $344.3M and net income of $9.0M. Profitability is improving, though the latest comparable-quarter revenue growth is modest. FairStock calculations at the 2026-10-13 close of $39.81 show a P/E of 38.28, P/B of 10.26, ROE of 30.42%, ROCE of 13.45%, debt-to-equity of 0.15, a Piotroski F-Score of 8/9, and an Altman Z-Score of 9.18. The balance sheet and returns look strong. But free cash flow yield is only 3.4%, EV/EBITDA is 19.30, and the Graham Number is $9.53, implying the price carries a large premium to a conservative value estimate. The PEG ratio of 0.51 looks attractive only if the supplied profit growth persists; I cannot verify it from two annual filings, and the Lynch category is 'none' because only two years of filed results exist. This may be a decent business with a narrow, unproven moat, but the price already assumes much.

In plain English: Guardian Pharmacy Services provides pharmacy and support services to long-term care facilities, including assisted living, behavioral health and group homes. The business has turned profitable and is growing, with low debt and good returns, but it has only a short public record. At the recent price, the stock looks expensive compared with its current profits and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer